All In MedTech

Device Trial Radar · NCT07950007

ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast Cancer

Individualized Neoadjuvant De-Escalation of T-DXd in HER2+ Breast Cancer (INDEX-HER2)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 1, 2027

Primary completion

Aug 1, 2029

Study completion Feb 1, 2034

Sponsor

Lead sponsor
Jin Sun BitarAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Natera, Inc.
First posted
Nov 20, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The convergence of evidence from neoCARHP (comparable pCR between TCHP and THP in an unselected population), DB-11 (activity of T-DXd-THP in high-risk HER2-positive early breast cancer), and I-SPY2 ctDNA data (early ctDNA clearance predicts favorable response and outcomes) provides a strong rationale for biomarker-guided treatment selection. This study uses early on-treatment ctDNA response after standardized THP induction to direct therapy intensity rather than reflexively escalating all patients. Unlike non-biomarker-selected escalation approaches, this study uses ctDNA as a dynamic biomarker to tailor therapy: patients with early molecular clearance continue THP without carboplatin or ADC exposure, while patients with persistent molecular tumor burden escalate to T-DXd.

Conditions

  • HER2 + Breast Cancer

Interventions

  • T-DXdDrug

    All patients begin with THP for Cycles 1-4. ctDNA is assessed at baseline,C2D1, C5D1, and at the preoperative and postoperative time points. C2D1 ctDNA determines subsequent treatment: ctDNA-negative patients continue THP through C6, while ctDNA-positive patients escalate to T-DXd from C5 through C8 after 4 cycles of THP.

  • ctDNA Testing Blood TestDevice

    A tumor-informed, personalized ctDNA assay will be used. Whole genome sequencing (WGS) will be performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue and matched-normal DNA from buffy coat to identify somatic variants. Based on the WGS results, multiplex PCR primers will be designed for 64 tumor-specific, somatic single-nucleotide variants for each patient. A sample will be considered ctDNA-positive if ≥2 of 64 variants are detected in the circulating cell-free DNA.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pCR rate in the HR-positive/HER2-positive groupTime frame: Time of Surgery, up to 24 weeks post on study

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Beverly Hills, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.